Tumor-infiltrating lymphocytes (TILs) have provided insight into the immunogenicity of breast tumors and have been shown to be useful as a prognostic biomarker in early-stage triple-negative and HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.